Search Site
Home >> Signaling Pathways >> Chromatin/Epigenetics >> JAK >> S-Ruxolitinib (INCB018424)
Related Products
S-Ruxolitinib (INCB018424)
JAK1/2 inhibitor,potent and selective

S-Ruxolitinib (INCB018424)

Catalog No. A4149
Size Price Stock Qty
5mg $170.00 In stock
10mg $230.00 In stock
50mg $650.00 In stock
200mg $1,490.00 In stock

Tel: +1-832-696-8203

Email: sales@apexbt.com

Worldwide Distributors

Sample solution is provided at 25 µL, 10mM.

Quality Control

Quality Control & MSDS

View current batch:

Chemical structure

S-Ruxolitinib (INCB018424)

Biological Activity

Description S-Ruxolitinib is the chirality of INCB018424.
Targets JAK1 JAK2 JAK3      
IC50 3.3 nM 2.8 nM 428 nM      

S-Ruxolitinib (INCB018424) Dilution Calculator

Concentration (start)
x
Volume (start)
=
Concentration (final)
x
Volume (final)
 
 
 
C1
V1
C2
V2

calculate

S-Ruxolitinib (INCB018424) Molarity Calculator

Mass
=
Concentration
x
Volume
x
MW*
 
 
 
g/mol

calculate

Chemical Properties

Cas No. 941685-37-6 SDF Download SDF
Chemical Name (3S)-3-cyclopentyl-3-[4-(7H-pyrrolo[2,3-d]pyrimidin-4-yl)pyrazol-1-yl]propanenitrile
Canonical SMILES C1CCC(C1)C(CC#N)N2C=C(C=N2)C3=C4C=CNC4=NC=N3
Formula C17H18N6 M.Wt 306.37
Solubility Soluble in DMSO > 10 mM Storage Store at -20°C
General tips For obtaining a higher solubility , please warm the tube at 37 ℃ and shake it in the ultrasonic bath for a while.Stock solution can be stored below -20℃ for several months.
Shipping Condition Evaluation sample solution : ship with blue ice
All other available size: ship with RT , or blue ice upon request

Background

S-Ruxolitinib is the chirality of INCB018424, is a potent and selective small-molecule Janus kinase 1 (JAK1) and JAK2 inhibitor. It was initially developed to target the constitutive activation of the JAK-STAT pathway. Janus kinases (JAKs) are a family of cytoplasmic tyrosine kinases that mediates signals from the receptors for various cytokines and growth factors that have a key role in haematopoiesis and immune function. Ruxolitinib maintains its anti-JAK activity by competitive inhibition of the ATP-binding catalytic site of the kinase domain. Ruxolitinib is well absorbed at >95%. Exposure of JAK2V617F-positive Ba/F3 cells to ruxolitinib iss shown to result in reduced cellular proliferation.

References

Ruben A. Mesa, Uma Yasothan, Peter Kirkpatrick. Ruxolitinib. Nature Reviews Drug Discovery. 2012; 11: 103-104

John Mascarenhas, Ronald Hoffman. Ruxolitinib: The First FDA Approved Therapy for the Treatment of Myelofibrosis. Clinical Cancer Research. 2012; 18(11): 3008 - 3014